Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS)
CNY 86.63
(-1.33%)
CNY 86.63
(-1.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 657.66 Million CNY | 480.81% |
| 2022 | 94.64 Million CNY | 291.11% |
| 2021 | -49.52 Million CNY | 85.37% |
| 2020 | -338.57 Million CNY | 13.88% |
| 2019 | -393.14 Million CNY | -300.1% |
| 2018 | -98.26 Million CNY | -153.26% |
| 2017 | -38.79 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 486.61 Million CNY | 28.82% |
| 2024 Q1 | 285.8 Million CNY | 49.67% |
| 2024 Q2 | 377.76 Million CNY | 32.17% |
| 2023 Q3 | 207.08 Million CNY | 12.64% |
| 2023 FY | 549.7 Million CNY | 480.81% |
| 2023 Q4 | 190.95 Million CNY | -7.79% |
| 2023 Q2 | 183.85 Million CNY | 401.17% |
| 2023 Q1 | 36.68 Million CNY | -50.28% |
| 2022 Q3 | 17.95 Million CNY | -63.68% |
| 2022 Q2 | 49.43 Million CNY | 227.81% |
| 2022 Q1 | -38.68 Million CNY | 65.63% |
| 2022 FY | 94.64 Million CNY | 291.11% |
| 2022 Q4 | 73.78 Million CNY | 310.92% |
| 2021 Q2 | -36.72 Million CNY | 16.05% |
| 2021 Q4 | -112.54 Million CNY | -152.38% |
| 2021 FY | -49.52 Million CNY | 85.37% |
| 2021 Q1 | -43.74 Million CNY | 58.58% |
| 2021 Q3 | 214.84 Million CNY | 685.01% |
| 2020 Q3 | -70.99 Million CNY | -4.07% |
| 2020 FY | -338.57 Million CNY | 13.88% |
| 2020 Q2 | -68.22 Million CNY | -3.99% |
| 2020 Q1 | -65.6 Million CNY | 50.66% |
| 2020 Q4 | -105.62 Million CNY | -48.77% |
| 2019 Q1 | -164.38 Million CNY | 0.0% |
| 2019 Q3 | -43.29 Million CNY | -6.6% |
| 2019 Q4 | -132.97 Million CNY | -207.12% |
| 2019 FY | -393.14 Million CNY | -300.1% |
| 2019 Q2 | -40.61 Million CNY | 75.29% |
| 2018 FY | -98.26 Million CNY | -153.26% |
| 2017 FY | -38.79 Million CNY | 0.0% |